TickerFacts.

Nexentis Technologies Inc. (NXTS): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$71.0K
Year ended 2025-12-31
$275.0K
Trailing 12 months to 2026-06-30
+9.4%
5-year compound annual growth
$75.6K2018-12-31: $75.6K2019-12-31: $27.4K2020-12-31: $45.2K2021-12-31: $57.2K2024-12-31: $18.0K2025-12-31: $71.0K$71.0K
2018-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$71.0K+294.4%2026-03-31, From 2025-01-01
2024-12-31$18.0Kn/a2026-03-31, From 2024-01-01
No annual figure between 2021-12-31 and 2024-12-31.
2021-12-31$57.2K+26.5%2022-03-31, From 2021-01-01
2020-12-31$45.2K+65.3%2022-03-31, From 2020-01-01
2019-12-31$27.4K-63.8%2021-03-29, From 2019-01-01
2018-12-31$75.6Kn/a2020-03-30, From 2018-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Nexentis Technologies Inc. (NXTS)2025-12-31$71.0K+294.4%
Incannex Healthcare Inc. (IXHL)2025-06-30$246.0K+138.8%
Jyong Biotech Ltd. (MENS)2025-12-31$100.0K-16.7%
Galectin Therapeutics Inc (GALT)2024-12-31$0n/a
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$39.0K+77.3%
Phio Pharmaceuticals Corp. (PHIO)2025-12-31$3.0K+50.0%
Lftd Partners Inc. (LIFD)2025-12-31$552.9K+6.2%
Moleculin Biotech, Inc. (MBRX)2025-12-31$90.0K-28.6%
Galmed Pharmaceuticals Ltd. (EOCN)2024-12-31$83.0K+167.7%

Compare NXTS, IXHL, MENS, GALT side by side · Screen every company in Pharmaceutical Preparations ↗